Dr Caroline Clarke (UCL Primary Care & Population Health) led a study finding that breast cancer patients who receive the drug Herceptin for nine weeks as part of their post-surgery chemotherapy regime may enjoy better health outcomes compared to those who receive it for the NHS-recommended 12 months.
Read: Mirror,
More: UCL News
Close
